Evidence map›Paper›PMID 41022479›Full record

ArticleCMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne2025

Cardiovascular risk thresholds for intensifying primary care encounter frequency for patients with type 2 diabetes mellitus: a target trial emulation.

Wanchun Xu, Emily Tsui Yee Tse, Peter Tanuseputro, Cindy Lo Kuen Lam, Eric Yuk Fai Wan

Abstract read
In one paragraph

Article in CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Wanchun XuDepartment of Family Medicine and Primary Care (Xu, Tse, Tanuseputro, Lam, Wan), Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China; Department of Family Medicine (Tse, Lam), The University of Hong Kong - Shenzhen Hospital, Shenzhen, China; Institut du Savoir Montfort (Tanuseputro), Ottawa, Ont.; Centre for Safe Medication Practice and Research (Wan), Department of Pharmacology and Pharmacy, and Institute of Cardiovascular Science and Medicine (Wan), Li Ka Shing Faculty of Medicine, The University of Hong Kong; Advanced Data Analytics for Medical Science Limited (Wan), Hong Kong Special Administrative Region, China.
Emily Tsui Yee TseDepartment of Family Medicine and Primary Care (Xu, Tse, Tanuseputro, Lam, Wan), Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China; Department of Family Medicine (Tse, Lam), The University of Hong Kong - Shenzhen Hospital, Shenzhen, China; Institut du Savoir Montfort (Tanuseputro), Ottawa, Ont.; Centre for Safe Medication Practice and Research (Wan), Department of Pharmacology and Pharmacy, and Institute of Cardiovascular Science and Medicine (Wan), Li Ka Shing Faculty of Medicine, The University of Hong Kong; Advanced Data Analytics for Medical Science Limited (Wan), Hong Kong Special Administrative Region, China.
Peter TanuseputroDepartment of Family Medicine and Primary Care (Xu, Tse, Tanuseputro, Lam, Wan), Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China; Department of Family Medicine (Tse, Lam), The University of Hong Kong - Shenzhen Hospital, Shenzhen, China; Institut du Savoir Montfort (Tanuseputro), Ottawa, Ont.; Centre for Safe Medication Practice and Research (Wan), Department of Pharmacology and Pharmacy, and Institute of Cardiovascular Science and Medicine (Wan), Li Ka Shing Faculty of Medicine, The University of Hong Kong; Advanced Data Analytics for Medical Science Limited (Wan), Hong Kong Special Administrative Region, China.
Cindy Lo Kuen LamDepartment of Family Medicine and Primary Care (Xu, Tse, Tanuseputro, Lam, Wan), Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China; Department of Family Medicine (Tse, Lam), The University of Hong Kong - Shenzhen Hospital, Shenzhen, China; Institut du Savoir Montfort (Tanuseputro), Ottawa, Ont.; Centre for Safe Medication Practice and Research (Wan), Department of Pharmacology and Pharmacy, and Institute of Cardiovascular Science and Medicine (Wan), Li Ka Shing Faculty of Medicine, The University of Hong Kong; Advanced Data Analytics for Medical Science Limited (Wan), Hong Kong Special Administrative Region, China.
Eric Yuk Fai WanDepartment of Family Medicine and Primary Care (Xu, Tse, Tanuseputro, Lam, Wan), Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China; Department of Family Medicine (Tse, Lam), The University of Hong Kong - Shenzhen Hospital, Shenzhen, China; Institut du Savoir Montfort (Tanuseputro), Ottawa, Ont.; Centre for Safe Medication Practice and Research (Wan), Department of Pharmacology and Pharmacy, and Institute of Cardiovascular Science and Medicine (Wan), Li Ka Shing Faculty of Medicine, The University of Hong Kong; Advanced Data Analytics for Medical Science Limited (Wan), Hong Kong Special Administrative Region, China. yfwan@hku.hk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDetermining optimal timing for intensifying the frequency of physician encounters for type 2 diabetes mellitus (T2DM) requires trade-offs between timely care and clinician burden. We aimed to investigate age-specific cardiovascular disease (CVD) risk thresholds used for intensifying encounter frequency in patients with T2DM in primary care.

methodsUsing population-based public electronic health records from the Hospital Authority Clinical Management System in Hong Kong, we used data from patients with a baseline 10-year CVD risk of lower than 20% and a regular follow-up interval of 4-6 months at public primary care clinics. We compared different CVD risk thresholds (> 20% v. 30%) at which to shorten follow-up intervals to 3 months or less. We investigated age-specific effects by categorizing patients into 4 age groups (< 50, 50-59, 60-69, and ≥ 70 yr). In the causal framework of the target trial emulation, we used a dynamic marginal structural model to estimate absolute risk differences for 5-year incidence of CVD, under the assumption of no unmeasured confounding.

resultsWe identified 44 813 patients. Compared with the risk threshold of 20%, adopting the threshold of 30% did not increase risk of overall CVD in patients younger than 50 years (absolute risk difference 0.2%, 95% confidence interval [CI] -0.6% to 1.0%]) and aged 50-59 years (absolute risk difference 0.7%, 95% CI -0.1% to 1.4%). However, we observed an increased risk in older patients, aged 60-69 years (absolute risk difference 1.5%, 95% CI 0.6% to 2.5%) and 70 years or older (absolute risk difference 2.7%, 95% CI 0.6% to 4.9%).

interpretationWhen adopting a less stringent CVD risk threshold of 30% to intensify encounter frequency, we found progressively increasing risks with age for 5-year CVD incidence, and age 60 years appears to be a point where the risk becomes pronounced. Our findings suggest that a less stringent threshold could be considered for patients with T2DM who are younger than 60 years but not for those older than 60 years.

Indexed as

Cardiovascular DiseasesDiabetes Mellitus, Type 2Primary Health CareAdultAgedAge FactorsElectronic Health RecordsFemaleHeart Disease Risk FactorsHong KongHumansIncidenceMaleMiddle AgedRisk AssessmentRisk Factors

Identifiers

PMID41022479
PMCPMC12483090

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.